I’m a long-term shareholder with a very large position relative to my means. I post rarely because I don’t want to dilute the message board with low value information or venting but I’m bending that here because I want to help other individual investors.
As individual investors we lack information relative to professionals but we have one key advantage. Patience. Professionals are constantly being judged on their short-term performance and could lose investors or get fired at any time. NWBO certainly tries our patience but, unlike most professionals, we can stay the course.
Nevertheless, I am upset by the lack of information from NWBO. Why not give us more info on Flaskworks and its progress? Why not give us information on many other questions that don’t relate directly to regulatory filings. A good example brought up by Hopeforthefuture regards revenue from the specials program. More than five years ago I was told by NWBO that that would likely happen within a few months. Glad I didn’t hold my breath on that one! FYI, it is my understanding that specials revenue is deducted from R&D expense and thus the reported R&D number is a net number.
I haven’t called the company in years. I think I spoke with Dave Innis once and quickly learned that that is not a fruitful endeavor. I will also say that this most recent ASM was by far the least informative of the three that I have attended. In the past, there was room to speak informally with management. That didn’t happen this time. Therefore, I feel the communication from the company has only become worse over time.
Additionally, while I don’t think Linda Powers is ripping off existing shareholders I will admit that I’m uncomfortable with the lack of clarity on the structure of the Advent relationship and certainly don’t feel good about Cognate.
So, you can see that despite having drunk the NWBO kool-aid, I feel a lot of frustration.
But, here’s my point. I ask fellow share holders and potential shareholders to keep your eyes on the ball. The science is wonderful and extremely undervalued. It seems to only get better with time. While we have relatively little information on manufacturing, the company has clearly said that automated manufacturing is a when rather than an if.
Regardless of your views of Linda Powers and management, she and her team have managed to keep NWBO alive despite at least ten years of relentless and likely illegal short activity. Regardless of what happens with the MHRA decision, there is now 100% probability that the company will be alive when that decision is made and the risk/reward at the current stock price is extremely favorable.
Market Data 
Markets 
AI
